Compugen Reaches Milestone with First Patient Dosed in COM701 Platinum-Sensitive Ovarian Cancer Trial
New York, NY – July 21, 2025 – Compugen Ltd., a clinical-stage drug discovery and development company, announced today a significant advancement in its pipeline with the successful dosing of the first patient in its global platform trial evaluating COM701 in platinum-sensitive ovarian cancer. This marks a crucial step forward for the company’s investigational immuno-oncology therapeutic candidate.
The platform trial is designed to explore the efficacy and safety of COM701, Compugen’s proprietary antibody targeting PVRIG, a protein expressed on tumor cells and immune cells that plays a role in immune evasion. By blocking the PVRIG pathway, COM701 aims to unleash the body’s own immune system to fight cancer. Ovarian cancer, particularly the platinum-sensitive subtype, represents a critical area of unmet medical need, and this trial signifies Compugen’s commitment to addressing this challenge.
“We are delighted to announce the initiation of this important global platform trial and the enrollment of the first patient,” said Dr. Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. “This trial represents a significant milestone for COM701 and underscores our dedication to advancing innovative therapies for patients with ovarian cancer. We believe that targeting the PVRIG pathway holds considerable promise, and we are eager to see the results of this comprehensive clinical evaluation.”
The trial is designed to enroll a broad range of patients with platinum-sensitive ovarian cancer, allowing for a thorough assessment of COM701’s potential benefits across diverse patient populations. The global nature of the trial ensures that a wide spectrum of clinical data will be gathered, providing valuable insights into COM701’s performance in various healthcare settings.
Platinum-sensitive ovarian cancer is a subtype of ovarian cancer that responds to platinum-based chemotherapy. However, many patients eventually develop resistance or recurrence, highlighting the ongoing need for novel treatment strategies. Compugen’s approach with COM701 aims to overcome these limitations by modulating the tumor microenvironment and enhancing anti-tumor immunity.
Compugen is committed to rigorous scientific investigation and patient-centric development. The company expresses its gratitude to the patients, investigators, and clinical sites participating in this vital trial. Further updates on the progress of the COM701 platform trial are anticipated as the study advances.
This announcement reflects Compugen’s ongoing efforts to build a robust immuno-oncology pipeline and deliver potentially transformative treatments to patients facing serious diseases. The successful initiation of this trial is a testament to the company’s scientific expertise and its unwavering focus on addressing critical unmet medical needs.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer’ at 2025-07-21 11:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.